Scholarlink

Background <p>Increased colorectal cancer (CRC) screening is needed to address high Alaska Native (AN) CRC rates. The study objective was to evaluate high-intensity vs. medium-intensity patient outreach using multi-target stool DNA (mt-sDNA) or colonoscopy.</p> Methods <p>A community-level, cluster-randomized clinical trial (April 29, 2021, through September 15, 2024) in 46 rural/remote Alaska communities. Participants were asymptomatic AN adults aged 45–75 with no family or personal history of CRC who were due for screening. High-intensity: Up to six patient navigator telephone calls with follow-up mailer. Medium-intensity: Mailed letter with one follow-up call. Usual care: Standard of care clinical visits. The primary outcome was screening completion within 12 months. Secondary outcomes included test preference, abnormal mt-sDNA follow-up colonoscopy, and colonoscopy outcomes.</p> Results <p>A total of 2029 AN people (mean [SD] age, 56 [8.4] years; 816 women [40%]) were randomized including 587 to usual care, 696 to medium-intensity, and 746 to the high-intensity arm. Both men and women were significantly more likely to request mt-sDNA (70%) over colonoscopy (30%, <i>p</i> &lt; 0.01), with participants ≥ 65 years old most likely to request mt-sDNA.</p> <p>Screening completion within 12 months among the total population was significantly higher in the medium-intensity (24%) and high-intensity arms (28%) compared with usual care (6%) (p&lt;0.01). Compared to usual care, CRC screening odds were higher with high-intensity (odds ratio [OR], 5.90; 95% CI, 3.86-9.04) and medium-intensity intervention (OR, 4.87; 95% CI, 3.18-7.46). Among those who agreed to screen, completion was similar in both intervention arms. Screening completion was 16% higher among high-intensity vs. medium-intensity participants (OR, 1.25; 95% CI, 0.91-1.71, p=0.19). Of the total eligible population, 254/2029 people (12.5%) had valid mt-sDNA tests and 278/2029 (13.7%) had complete colonoscopies. CRC/advanced neoplasia was found in over 25% of initial screening colonoscopies and 59% of colonoscopies performed after abnormal mt-sDNA.</p> Conclusions <p>Both a medium- and a high-intensity intervention were significantly more effective at increasing screening initiation and completion rates compared with usual care in rural/remote Alaskan communities. Participants significantly preferred mt-sDNA for screening. These findings highlight the clinical utility of focused outreach strategies in primary care settings and support the use of mt-sDNA as a viable alternative to colonoscopy in geographically isolated populations.</p> Trial registration <p>The study is registered with the Clinical Trials Registry (Stool DNA to Improve Colorectal Cancer Screening Among Alaska Native People, NCT04336397, https//www.cancer.gov/research/participate/clinicaltrialssearch/v? id=NCI202108691, registration date 04/03/2020) and was designed in accordance with the Consolidated Standards of Reporting Trials (CONSORT) statement.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Increasing colorectal cancer screening among Alaska Native peoples living in remote areas of Alaska: a multitarget stool DNA cluster randomized controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月26日

查看全文
  • Diana Redwood,
  • Christie Flanagan,
  • Lauren Jeffries,
  • Peter Holck,
  • Lila Finney Rutten,
  • Christine Desnoyers,
  • Danika Bailie,
  • John Kisiel

摘要

Background

Increased colorectal cancer (CRC) screening is needed to address high Alaska Native (AN) CRC rates. The study objective was to evaluate high-intensity vs. medium-intensity patient outreach using multi-target stool DNA (mt-sDNA) or colonoscopy.

Methods

A community-level, cluster-randomized clinical trial (April 29, 2021, through September 15, 2024) in 46 rural/remote Alaska communities. Participants were asymptomatic AN adults aged 45–75 with no family or personal history of CRC who were due for screening. High-intensity: Up to six patient navigator telephone calls with follow-up mailer. Medium-intensity: Mailed letter with one follow-up call. Usual care: Standard of care clinical visits. The primary outcome was screening completion within 12 months. Secondary outcomes included test preference, abnormal mt-sDNA follow-up colonoscopy, and colonoscopy outcomes.

Results

A total of 2029 AN people (mean [SD] age, 56 [8.4] years; 816 women [40%]) were randomized including 587 to usual care, 696 to medium-intensity, and 746 to the high-intensity arm. Both men and women were significantly more likely to request mt-sDNA (70%) over colonoscopy (30%, p < 0.01), with participants ≥ 65 years old most likely to request mt-sDNA.

Screening completion within 12 months among the total population was significantly higher in the medium-intensity (24%) and high-intensity arms (28%) compared with usual care (6%) (p<0.01). Compared to usual care, CRC screening odds were higher with high-intensity (odds ratio [OR], 5.90; 95% CI, 3.86-9.04) and medium-intensity intervention (OR, 4.87; 95% CI, 3.18-7.46). Among those who agreed to screen, completion was similar in both intervention arms. Screening completion was 16% higher among high-intensity vs. medium-intensity participants (OR, 1.25; 95% CI, 0.91-1.71, p=0.19). Of the total eligible population, 254/2029 people (12.5%) had valid mt-sDNA tests and 278/2029 (13.7%) had complete colonoscopies. CRC/advanced neoplasia was found in over 25% of initial screening colonoscopies and 59% of colonoscopies performed after abnormal mt-sDNA.

Conclusions

Both a medium- and a high-intensity intervention were significantly more effective at increasing screening initiation and completion rates compared with usual care in rural/remote Alaskan communities. Participants significantly preferred mt-sDNA for screening. These findings highlight the clinical utility of focused outreach strategies in primary care settings and support the use of mt-sDNA as a viable alternative to colonoscopy in geographically isolated populations.

Trial registration

The study is registered with the Clinical Trials Registry (Stool DNA to Improve Colorectal Cancer Screening Among Alaska Native People, NCT04336397, https//www.cancer.gov/research/participate/clinicaltrialssearch/v? id=NCI202108691, registration date 04/03/2020) and was designed in accordance with the Consolidated Standards of Reporting Trials (CONSORT) statement.